Understanding Factor V Leiden, also known as Factor V Leiden mutation or APC resistance, is crucial for accurate clinical documentation and medical coding. This hereditary thrombophilia increases the risk of blood clots. Learn about Factor V Leiden diagnosis, testing, and management, including relevant ICD-10 codes and SNOMED CT terms for healthcare professionals. Explore resources for proper documentation of Factor V Leiden and its associated complications for optimal patient care.
Also known as
Factor V Leiden thrombophilia
Inherited disorder increasing blood clot risk.
Personal history of other coagulation defects
Past diagnosis of a blood clotting disorder, including Factor V Leiden.
Other specified venous embolism and thrombosis
Venous blood clots, potentially related to Factor V Leiden.
Follow this step-by-step guide to choose the correct ICD-10 code.
Is Factor V Leiden confirmed by testing?
When to use each related code
| Description |
|---|
| Inherited blood clotting disorder |
| Acquired blood clotting disorder |
| Inherited protein C deficiency |
Coding F5 without specifying heterozygous or homozygous status (e.g., Z86.710, Z86.711) leads to inaccurate risk assessment and reimbursement.
Discrepancy between documented patient history of thrombosis and F5 diagnosis may indicate coding or documentation errors impacting quality metrics.
Coding F5 based on presumptive diagnosis without confirmatory genetic testing lacks coding integrity and can trigger audit scrutiny. Consider Z13.818.
Q: How does Factor V Leiden mutation impact anticoagulation management in patients requiring long-term therapy?
A: Factor V Leiden, a common inherited thrombophilia, significantly influences anticoagulation management. Patients with Factor V Leiden mutation exhibit resistance to activated protein C (APC), a key regulator of coagulation. This resistance increases their risk of venous thromboembolism (VTE) recurrence, especially during periods of prolonged anticoagulation. Clinicians managing patients with Factor V Leiden on long-term anticoagulation must carefully consider the patient's individual risk factors, including the presence of homozygous or heterozygous Factor V Leiden, concomitant thrombophilic disorders, and prior VTE history. In some cases, higher target INR ranges or extended durations of anticoagulation may be warranted. Explore how personalized medicine approaches are being used to optimize anticoagulation strategies in patients with Factor V Leiden. Consider implementing strategies for enhanced monitoring and patient education to ensure optimal therapeutic outcomes and minimize bleeding risks.
Q: What are the key differential diagnoses to consider when a patient presents with suspected Factor V Leiden and what diagnostic tests are most appropriate?
A: When a patient presents with clinical suspicion for Factor V Leiden, it's essential to consider other inherited and acquired thrombophilias in the differential diagnosis. These may include prothrombin G20210A mutation, protein C or S deficiency, antithrombin deficiency, and antiphospholipid syndrome. Distinguishing between these conditions requires a comprehensive approach. The most appropriate diagnostic test for Factor V Leiden is the APC resistance assay, often followed by genetic testing to confirm the presence of the specific mutation. However, interpreting these results in the context of acute thrombosis requires careful consideration, as acutely ill patients might display altered coagulation parameters. Consider implementing a stepwise diagnostic algorithm that includes a thorough clinical evaluation, family history assessment, and targeted laboratory testing based on pretest probability. Learn more about the interpretation of APC resistance assays and the role of genetic testing in confirming Factor V Leiden diagnosis.
Patient presents with concerns regarding Factor V Leiden thrombophilia, also known as activated protein C resistance or APC resistance. This hereditary thrombophilia increases the risk of venous thromboembolism (VTE), including deep vein thrombosis (DVT) and pulmonary embolism (PE). Family history is positive for DVT. Patient denies any current symptoms of DVT or PE, such as leg pain, swelling, or shortness of breath. Physical examination is unremarkable. Factor V Leiden genetic testing was ordered to assess the presence of the Factor V Leiden mutation. Diagnosis of Factor V Leiden mutation was confirmed by molecular genetic testing. Patient education provided regarding the increased risk of thrombosis, preventative measures, and signs and symptoms of VTE. Discussed the importance of informing healthcare providers of this diagnosis prior to any surgical procedures, pregnancy, or starting hormonal therapy. No anticoagulation therapy is indicated at this time due to the absence of current thrombotic events. Patient advised to avoid prolonged immobility, maintain hydration, and consider compression stockings during long-distance travel as prophylactic measures. Follow-up appointment scheduled to reassess risk factors and discuss long-term management. ICD-10 code I82.21 for Factor V Leiden mutation specified for medical billing and coding purposes.